Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

181 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapeutic treatment with the anti-inflammatory drug candidate MW151 may partially reduce memory impairment and normalizes hippocampal metabolic markers in a mouse model of comorbid amyloid and vascular pathology.
Braun DJ, Powell DK, McLouth CJ, Roy SM, Watterson DM, Van Eldik LJ. Braun DJ, et al. Among authors: watterson dm. PLoS One. 2022 Jan 26;17(1):e0262474. doi: 10.1371/journal.pone.0262474. eCollection 2022. PLoS One. 2022. PMID: 35081152 Free PMC article.
Involvement of p38 MAPK in Synaptic Function and Dysfunction.
Falcicchia C, Tozzi F, Arancio O, Watterson DM, Origlia N. Falcicchia C, et al. Among authors: watterson dm. Int J Mol Sci. 2020 Aug 6;21(16):5624. doi: 10.3390/ijms21165624. Int J Mol Sci. 2020. PMID: 32781522 Free PMC article. Review.
Correction to "A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction".
Roy SM, Minasov G, Arancio O, Chico LW, Van Eldik LJ, Anderson WF, Pelletier JC, Watterson DM. Roy SM, et al. Among authors: watterson dm. J Med Chem. 2020 Aug 13;63(15):8649. doi: 10.1021/acs.jmedchem.0c01060. Epub 2020 Jul 16. J Med Chem. 2020. PMID: 32672466 Free PMC article. No abstract available.
First-in-Human Studies of MW01-6-189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers.
Van Eldik LJ, Sawaki L, Bowen K, Laskowitz DT, Noveck RJ, Hauser B, Jordan L, Spears TG, Wu H, Watt K, Raja S, Roy SM, Watterson DM, Guptill JT. Van Eldik LJ, et al. Among authors: watterson dm. Clin Pharmacol Drug Dev. 2021 Feb;10(2):131-143. doi: 10.1002/cpdd.795. Epub 2020 Apr 7. Clin Pharmacol Drug Dev. 2021. PMID: 32255549 Free PMC article. Clinical Trial.
A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction.
Roy SM, Minasov G, Arancio O, Chico LW, Van Eldik LJ, Anderson WF, Pelletier JC, Watterson DM. Roy SM, et al. Among authors: watterson dm. J Med Chem. 2019 Jun 13;62(11):5298-5311. doi: 10.1021/acs.jmedchem.9b00058. Epub 2019 Apr 23. J Med Chem. 2019. PMID: 30978288 Free PMC article. Review.
181 results